# Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

> **NCT05040360** · PHASE2 · RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 141 (estimated)

## Conditions studied

- Metastatic Malignant Neoplasm in the Liver
- Pancreatic Neuroendocrine Tumor
- Stage I Pancreatic Neuroendocrine Tumor AJCC v8
- Stage II Pancreatic Neuroendocrine Tumor AJCC v8
- Stage III Pancreatic Neuroendocrine Tumor AJCC v8

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05040360
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-05
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 141 (ESTIMATED)
- **Last updated:** 2025-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040360, "Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05040360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*